Key Drivers
- Cash Reserves
- Cash Burn
- Share Dilution
AIAI Summary
MLYS has shifted from a speculative pre-commercial biotech to a near-term FDA catalyst trade with enough cash to reach the PDUFA date, but the stock remains a binary bet on approval and launch execution while ongoing burn and dilution cap downside protection and upside visibility.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Reserves
- •Cash Burn
- •Share Dilution
MLYS has a very strong cash-rich, debt-free balance sheet, but ongoing losses, zero revenue, negative cash flow, and dilution are steadily eroding per-share value.
Price Behavior
Key Price Behavior Insights:
- •Range-bound trade
- •$30 failure
- •Dips bought
Over the last month, MLYS has been volatile and range-bound, with sharp bounces off the mid-$25s but repeated failure near $30, leaving the next move dependent on whether $26.6-$27.3 support holds or breaks.
Sharp rebound from $25.56 to $30.12, then a quick drop back below $27
Sentiment & News
Key News Insights:
- •FDA filing
- •Q1 update
- •Investor outreach
Mineralys reported Q1 2026 results and, more importantly, FDA acceptance of its lorundrostat NDA with a PDUFA date of 2026-12-22, marking a key regulatory milestone.
This news is modestly positive for Mineralys, as NDA acceptance meaningfully de-risks the path to a potential approval decision later in 2026
Similar Companies in Healthcare
Other companies in the same sector with AI ratings